[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642580":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":34,"locations":44,"responsibleParty":63,"collaborators":26,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":26,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":26,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":47,"whyStopped":26,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Shenyang Sunshine Pharmaceutical Co., LTD.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1","EXPERIMENTAL","advanced cancer that have failed standard treatment",[13,14],"Drug: SSGJ-705","Drug: SSGJ-612",{"label":16,"type":10,"description":17,"interventionNames":18},"Part 2","previously untreated advanced gastric cancer",[14,19],"Drug: SSGJ-705 combined with chemotherapy",[21,27,31],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","SSGJ-705","anti-PD-1 and anti-HER2 bispecifc antibody",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"SSGJ-612","anti-HER2 antibody",[9,16],{"type":22,"name":32,"description":32,"armGroupLabels":33,"otherNames":26},"SSGJ-705 combined with chemotherapy",[16],[35,40],{"name":36,"role":37,"phone":38,"phoneExt":26,"email":39},"Jieer Ying, M.D.","CONTACT","+86-13858195803","hzyingjieer@163.com",{"name":41,"role":37,"phone":42,"phoneExt":26,"email":43},"Meifang Zheng, M.D.","+86-15258894828","794998553@qq.com",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":26,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Zhejiang Cancer Hospital","RECRUITING","Hangzhou","Zhejiang","China","CN",{"type":53,"coordinates":54},"Point",[55,56],120.16142,30.29365,{"lat":56,"lon":55},[59],{"name":60,"role":37,"phone":61,"phoneExt":26,"email":62},"Feiyan Li","0571-88122482","lify1697@zjcc.org.cn",{"type":64,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100642580","phase-2-ssgj-705-plus-ssgj-612--chemotherapy-in-advanced-her2-expressing-solid-tumors-100642580",false,"NCT07646626","SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors","A Phase II Study of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors","Inclusion Criteria:\n\n* Males and\u002For females over age 18\n* Histologically and\u002For cytologically documented local advanced or metastatic Colorectal adenocarcinoma (CRC), Urothelial Cancer (UC), Breast Cancer (BC), Biliary Tract Carcinoma(BTC), Gastric\u002FGastroesophageal Junction Cancer （G\u002FGEJC) , etc.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Expected survival \\>3 months.\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Any remaining adverse events (AEs) \\> grade 1 from prior anti-tumor treatment as per Common Terminology Criteria for Adverse Events（CTCAE） v6. 0, with exception of hair loss, fatigue, and grade 2 peripheral neurotoxicity.\n* Pregnant or nursing women or women\u002Fmen who are ready to give birth\n* symptomatic central nervous system metastasis.\n* Allergy to other antibody drugs or any excipients in the study drugs.\n* Inadequate organ or bone marrow function. The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","ALL","18 Years","75 Years",{"count":76,"type":77},150,"ESTIMATED","INTERVENTIONAL",[80],"PHASE2","This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in patients with advanced HER2-Expressing Solid Tumors.",[83],"Locally Advanced (Unresectable) or Metastatic Solid Tumors",[85],"advanced malignancies","2026-06-08",{"date":88,"type":89},"2026-06-15","ACTUAL",{"date":91,"type":77},"2026-07-31",{"date":93,"type":77},"2028-10-31",{"name":5,"class":6},1]